1. Microbial protein cell factories fight back?
- Author
-
Lukas A. Rettenbacher, Klaudia Arauzo-Aguilera, Luisa Buscajoni, Angel Castillo-Corujo, Borja Ferrero-Bordera, Aliki Kostopoulou, Rafael Moran-Torres, David Núñez-Nepomuceno, Ayşegül Öktem, Arianna Palma, Beatrice Pisent, Martina Puricelli, Tobias Schilling, Aatir A. Tungekar, Jonathan Walgraeve, David Humphreys, Tobias von der Haar, Brigitte Gasser, Diethard Mattanovich, Lloyd Ruddock, and Jan Maarten van Dijl
- Subjects
0106 biological sciences ,Mammals ,Biological Products ,0303 health sciences ,Systems Biology ,Post-Translational ,Proteins ,Bioengineering ,01 natural sciences ,03 medical and health sciences ,010608 biotechnology ,Biological Products/metabolism ,Animals ,Proteins/metabolism ,Protein Processing, Post-Translational ,Protein Processing ,030304 developmental biology ,Biotechnology - Abstract
The biopharmaceutical market is growing faster than ever, with two production systems competing for market dominance: mammalian cells and microorganisms. In recent years, based on the rise of antibody-based therapies, new biotherapeutic approvals have favored mammalian hosts. However, not only has extensive research elevated our understanding of microbes to new levels, but emerging therapeutic molecules also facilitate their use; thus, is it time for microbes to fight back? In this review, we answer this timely question by cross-comparing four microbial production hosts and examining the innovations made to both their secretion and post-translational modification (PTM) capabilities. Furthermore, we discuss the impact of tools, such as omics and systems biology, as well as alternative production systems and emerging biotherapeutics.
- Full Text
- View/download PDF